Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study; Termination of Biogen Collaboration
- Results from XLRS study support general safety and tolerability of AGTC’s gene delivery platform but did not demonstrate signs of clinical activity at interim six-month time point - -  AGTC to regain rights to five clinical and preclinical development programs; Biogen terminates collaboration
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 8, 2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC to Present at Upcoming Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC Appoints William Aliski to its Board of Directors
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced it
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 10, 2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 15, 2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns $10 Million Enrollment Milestone
Company Provides Pipeline Enrollment Update for Clinical Trials in Inherited Retinal Diseases GAINESVILLE, Fla. and CAMBRIDGE, Mass. , July 23, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of
View HTML
Toggle Summary AGTC Announces Expansion of Clinical and Medical Leadership Teams
20+ Year Medical Affairs and Ophthalmology Veteran, Lanita C. Scott , M.D., Appointed as Vice President of Clinical Research and Medical Affairs Karen M. Carroll, RN , Named Vice President of Clinical Development Operations GAINESVILLE, Fla. and CAMBRIDGE, Mass.
View HTML
Visionary science for life changing cures.